Biological Products, (No Diagnostic Substances) Industry - SEC Form 4 Insider Trading Screener
Manufacturing Sector - Chemicals - Biological Products, (No Diagnostic Substances)
100 results - 
- 
- 
- 
- 
- 
- 
- - - - - - | TC | cnt | 1d | 1w | 1m | 6m |
X |
Filing Date |
Trade Date |
Ticker |
Company | Insider Name | Insider Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2019-10-10 | DYAI | Dyadic International Inc | Tchelet Ronen | VP of Research, Bus. Dvlpmt | S - Sale+OE | $6.06 | -10,000 | 0 | -100% | -$60,609 | |||||
2019-10-09 | BCDA | Biocardia, Inc. | Altman Peter | Pres, CEO | P - Purchase | $3.99 | +200 | 159,211 | 0% | +$798 | ||||||
| D | 2019-10-08 | SGEN | Seattle Genetics Inc /wa | Siegall Clay B | Pres, CEO | S - Sale+OE | $82.47 | -28,472 | 755,684 | -4% | -$2,348,061 | |||||
2019-10-07 | BLUE | Bluebird Bio, Inc. | Gregory Philip D | Chief Scientific Officer | S - Sale | $89.07 | -250 | 29,592 | -1% | -$22,267 | ||||||
| M | 2019-10-04 | VXRT | Vaxart, Inc. | Armistice Capital, LLC | 10% | P - Purchase | $0.36 | +564,000 | 50,000,000 | +1% | +$203,200 | |||||
| M | 2019-10-03 | BCDA | Biocardia, Inc. | Altman Peter | Pres, CEO | P - Purchase | $3.47 | +5,700 | 159,011 | +4% | +$19,771 | |||||
2019-10-02 | NBIX | Neurocrine Biosciences Inc | Cooke Julie | CHRO | S - Sale | $88.56 | -987 | 3,276 | -23% | -$87,409 | ||||||
2019-10-02 | CDTX | Cidara Therapeutics, Inc. | Daruwala Paul | COO | S - Sale | $1.88 | -3,295 | 55,872 | -6% | -$6,195 | ||||||
2019-10-01 | CDTX | Cidara Therapeutics, Inc. | Abdollahian Neil | Chief Business Officer | S - Sale | $1.98 | -7,284 | 49,588 | -13% | -$14,422 | ||||||
| D | 2019-10-01 | SGEN | Seattle Genetics Inc /wa | Gryska David W | Dir | S - Sale+OE | $85.09 | -5,000 | 48,013 | -9% | -$425,450 | |||||
| M | 2019-10-01 | VXRT | Vaxart, Inc. | Armistice Capital, LLC | 10% | P - Purchase | $0.35 | +436,000 | 48,872,000 | +1% | +$150,552 | |||||
| D | 2019-10-02 | AMGN | Amgen Inc | Sugar Ronald D | Dir | S - Sale+OE | $193.58 | -2,000 | 14,436 | -12% | -$387,160 | |||||
| DM | 2019-10-01 | TWST | Twist Bioscience Corp | Weiss Patrick | SVP, R, D GM Data Storage | S - Sale+OE | $22.86 | -14,729 | 105,287 | -12% | -$336,689 | |||||
2019-10-01 | TWST | Twist Bioscience Corp | Peck Bill | CTO | S - Sale | $23.13 | -20,000 | 663,332 | -3% | -$462,590 | ||||||
| D | 2019-10-01 | VCEL | Vericel Corp | Colangelo Dominick | Pres, CEO | S - Sale+OE | $14.88 | -58,125 | 112,783 | -34% | -$864,650 | |||||
2019-09-30 | SGEN | Seattle Genetics Inc /wa | Simpson Todd E | CFO | S - Sale | $85.00 | -15,000 | 157,567 | -9% | -$1,275,000 | ||||||
2019-09-30 | SGEN | Seattle Genetics Inc /wa | Liu Jean I | GC, EVP, Leg Affairs | S - Sale | $86.00 | -7,432 | 70,688 | -10% | -$639,152 | ||||||
2019-09-27 | CDTX | Cidara Therapeutics, Inc. | Oien Jessica | GC, Secretary | S - Sale | $1.86 | -1,001 | 7,799 | -11% | -$1,862 | ||||||
2019-09-27 | PTE | Polarityte, Inc. | Hague Richard | COO | S - Sale | $3.56 | -2,402 | 337,423 | -1% | -$8,551 | ||||||
2019-09-27 | PTE | Polarityte, Inc. | Hoyler Cameron J. | GC | S - Sale | $3.56 | -281 | 346,604 | 0% | -$1,000 | ||||||
| M | 2019-09-26 | VXRT | Vaxart, Inc. | Armistice Capital, LLC | 10% | P - Purchase | $0.29 | +7,333,333 | 48,000,000 | +18% | +$2,143,078 | |||||
| D | 2019-09-30 | VXRT | Vaxart, Inc. | Latour Wouter | Pres, Chief Exec | P - Purchase | $0.30 | +166,667 | 166,667 | New | +$50,000 | |||||
2019-09-27 | ATRA | Atara Biotherapeutics, Inc. | Newell Joe | Chief Tech. Operations Officer | S - Sale | $13.51 | -3,500 | 57,998 | -6% | -$47,285 | ||||||
2019-09-25 | SGEN | Seattle Genetics Inc /wa | Dansey Roger D | Chief Medical Officer | S - Sale | $73.80 | -3,000 | 103,146 | -3% | -$221,415 | ||||||
2019-09-24 | CDTX | Cidara Therapeutics, Inc. | Stein Jeffrey | Pres, CEO | P - Purchase | $1.91 | +52,500 | 523,648 | +11% | +$100,102 | ||||||
2019-09-24 | CDTX | Cidara Therapeutics, Inc. | Levine James E. | CFO | P - Purchase | $1.91 | +30,000 | 205,000 | +17% | +$57,240 | ||||||
| M | 2019-09-25 | TWST | Twist Bioscience Corp | Finn Patrick John | SVP, Commercial Operations | S - Sale | $25.43 | -37,000 | 5,002 | -88% | -$941,043 | |||||
2019-09-23 | BOLD | Audentes Therapeutics, Inc. | Lange Louis G | Dir | S - Sale | $32.16 | -11,000 | 326,375 | -3% | -$353,798 | ||||||
2019-09-23 | PTE | Polarityte, Inc. | Hoyler Cameron J. | GC | S - Sale | $4.30 | -3,500 | 346,885 | -1% | -$15,050 | ||||||
2019-09-23 | PTE | Polarityte, Inc. | Mann Paul Elliot | CFO | S - Sale | $4.30 | -1,283 | 464,227 | 0% | -$5,517 | ||||||
2019-09-23 | REPL | Replimune Group, Inc. | Astley-Sparke Philip | Exec COB | S - Sale | $17.05 | -14,500 | 1,427,797 | -1% | -$247,225 | ||||||
2019-09-23 | REPL | Replimune Group, Inc. | Love Colin | COO | S - Sale | $17.05 | -11,250 | 1,107,774 | -1% | -$191,813 | ||||||
2019-09-23 | REPL | Replimune Group, Inc. | Coffin Robert | Pres, CEO | S - Sale | $17.05 | -24,250 | 2,387,868 | -1% | -$413,463 | ||||||
2019-09-23 | CHRS | Coherus Biosciences, Inc. | Viret Jean-Frederic | CFO | S - Sale | $21.78 | -740 | 7,773 | -9% | -$16,117 | ||||||
| M | 2019-09-20 | TCRR | Tcr2 Therapeutics Inc. | Jovan-Embiricos Morana | 10% | S - Sale | $17.92 | -416,321 | 1,605,398 | -21% | -$7,459,819 | |||||
| D | 2019-09-20 | ALEC | Alector, Inc. | Oney Sabah | Chief Business Officer | S - Sale+OE | $20.00 | -400 | 593,918 | 0% | -$8,000 | |||||
| D | 2019-09-20 | ALEC | Alector, Inc. | Paul Robert | Chief Medical Officer | S - Sale+OE | $20.00 | -4,000 | 311,719 | -1% | -$80,000 | |||||
2019-09-19 | VBIV | Vbi Vaccines Inc. | Gillis Steven | Dir | P - Purchase | $0.50 | +10,000,000 | 13,110,473 | +321% | +$5,000,000 | ||||||
| D | 2019-09-19 | RGEN | Repligen Corp | Hunt Anthony | CEO | S - Sale+OE | $82.89 | -3,600 | 219,413 | -2% | -$298,390 | |||||
2019-09-18 | OTLK | Outlook Therapeutics, Inc. | Kenyon Lawrence A | CEO, Pres, CFO, Treas, Secy | S - Sale | $1.70 | -1,350 | 80,863 | -2% | -$2,295 | ||||||
| D | 2019-09-19 | RGNX | Regenxbio Inc. | Mills Kenneth T. | Pres, CEO | S - Sale+OE | $39.75 | -10,000 | 241,000 | -4% | -$397,497 | |||||
| D | 2019-09-18 | CHRS | Coherus Biosciences, Inc. | Viret Jean-Frederic | CFO | S - Sale+OE | $20.44 | -3,159 | 8,513 | -27% | -$64,560 | |||||
| D | 2019-09-17 | SWTX | Springworks Therapeutics, Inc. | Squinto Stephen P | Dir, 10% | P - Purchase | $18.00 | +275,000 | 7,406,307 | +4% | +$4,950,000 | |||||
| D | 2019-09-17 | SWTX | Springworks Therapeutics, Inc. | Lewis-Hall Freda C | Dir, 10% | P - Purchase | $18.00 | +50,000 | 8,611,092 | +1% | +$900,000 | |||||
| D | 2019-09-17 | SWTX | Springworks Therapeutics, Inc. | Orbimed Advisors LLC | 10% | P - Purchase | $18.00 | +275,000 | 7,406,307 | +4% | +$4,950,000 | |||||
| D | 2019-09-17 | SWTX | Springworks Therapeutics, Inc. | Bain Capital Life Sciences Investors, LLC | 10% | P - Purchase | $18.00 | +150,000 | 7,281,307 | +2% | +$2,700,000 | |||||
| DM | 2019-09-17 | TWST | Twist Bioscience Corp | Weiss Patrick | SVP, R, D GM Data Storage | S - Sale+OE | $29.78 | -14,728 | 105,287 | -12% | -$438,659 | |||||
| DM | 2019-09-16 | RUBY | Rubius Therapeutics, Inc. | Carpenter Christopher L. | Chief Medical Officer | S - Sale+OE | $10.11 | -48,000 | 34,843 | -58% | -$485,206 | |||||
| DM | 2019-09-16 | ALLO | Allogene Therapeutics, Inc. | Moore Alison | Chief Technical Officer | S - Sale+OE | $32.11 | -48,827 | 66,067 | -42% | -$1,567,666 | |||||
2019-09-16 | ALEC | Alector, Inc. | Paul Robert | Chief Medical Officer | S - Sale | $19.08 | -10,000 | 311,719 | -3% | -$190,800 | ||||||
2019-09-17 | CVM | Cel Sci Corp | Cipriano John | SVP | S - Sale | $8.69 | -8,000 | 83,108 | -9% | -$69,559 | ||||||
| M | 2019-09-16 | TWST | Twist Bioscience Corp | Banyai William | COO | S - Sale | $29.86 | -22,000 | 703,461 | -3% | -$656,949 | |||||
2019-09-17 | NVAX | Novavax Inc | Herrmann John A III | SVP, GC | S - Sale | $7.07 | -3,643 | 0 | -100% | -$25,757 | ||||||
| D | 2019-09-17 | MRNA | Moderna, Inc. | Hutt Peter Barton | Dir | S - Sale+OE | $17.63 | -100,000 | 3,924 | -96% | -$1,763,000 | |||||
| D | 2019-09-16 | CHRS | Coherus Biosciences, Inc. | Anicetti Vincent R | COO | S - Sale+OE | $20.03 | -2,500 | 19,310 | -11% | -$50,075 | |||||
2019-09-16 | TWST | Twist Bioscience Corp | Daniels Mark | SVP, GC | S - Sale | $29.90 | -1,500 | 51,355 | -3% | -$44,850 | ||||||
| M | 2019-09-13 | TWST | Twist Bioscience Corp | Peck Bill | CTO | S - Sale | $30.06 | -19,553 | 683,332 | -3% | -$587,686 | |||||
2019-09-16 | FATE | Fate Therapeutics Inc | Redmile Group, LLC | Dir, 10% | P - Purchase | $17.50 | +857,143 | 11,216,809 | +8% | +$15,000,003 | ||||||
2019-09-13 | ALDX | Aldeyra Therapeutics, Inc. | Douglas Richard | Dir | P - Purchase | $6.00 | +5,000 | 85,000 | +6% | +$30,000 | ||||||
2019-09-16 | BIEI | Premier Biomedical Inc | Felder Mitchell S | COB, 10% | P - Purchase | $0.01 | +1,000,000 | 3,334,488 | +43% | +$9,222 | ||||||
| D | 2019-09-12 | RGNX | Regenxbio Inc. | Christmas Patrick J. | SVP, GC | S - Sale+OE | $42.00 | -5,486 | 2,572 | -68% | -$230,412 | |||||
2019-09-13 | NVAX | Novavax Inc | Glenn Gregory M | Pres, R, D | S - Sale | $6.18 | -9,620 | 123 | -99% | -$59,476 | ||||||
2019-09-13 | NSTG | Nanostring Technologies Inc | Waite Charles P Jr | Dir | S - Sale | $21.75 | -1,707 | 0 | -100% | -$37,130 | ||||||
2019-09-11 | OCX | Oncocyte Corp | Lineage Cell Therapeutics, Inc. | 10% | S - Sale | $1.66 | -4,000,000 | 8,424,244 | -32% | -$6,640,000 | ||||||
| M | 2019-09-11 | ALDX | Aldeyra Therapeutics, Inc. | Douglas Richard | Dir | P - Purchase | $5.89 | +20,000 | 80,000 | +33% | +$117,805 | |||||
| D | 2019-09-10 | DYAI | Dyadic International Inc | Tchelet Ronen | VP of Research, Bus. Dvlpmt | S - Sale+OE | $5.27 | -10,000 | 0 | -100% | -$52,700 | |||||
2019-09-11 | INMB | Inmune Bio, Inc. | Lowdell Mark William | Chief Scientific Officer, 10% | P - Purchase | $6.23 | +2,918 | 1,506,251 | 0% | +$18,179 | ||||||
2019-09-11 | NVAX | Novavax Inc | Trizzino John | SVP, CBO, CFO | S - Sale | $5.72 | -5,578 | 4,800 | -54% | -$31,911 | ||||||
2019-09-11 | BIEI | Premier Biomedical Inc | Felder Mitchell S | COB, 10% | P - Purchase | $0.01 | +1,006,457 | 2,334,488 | +76% | +$8,566 | ||||||
2019-09-09 | RGEN | Repligen Corp | Hunt Anthony | CEO | S - Sale | $82.40 | -12,094 | 203,013 | -6% | -$996,521 | ||||||
| D | 2019-09-09 | TECH | Bio-Techne Corp | Kummeth Charles R. | CEO | P - Purchase | $185.00 | +200 | 136,056 | 0% | +$37,000 | |||||
2019-09-09 | DNLI | Denali Therapeutics Inc. | Schuth Alexander O. | COO, Secretary | S - Sale | $18.16 | -7,500 | 630,799 | -1% | -$136,200 | ||||||
| DM | 2019-09-09 | BLUE | Bluebird Bio, Inc. | Davidson David | Chief Medical Officer | S - Sale+OE | $100.13 | -5,060 | 31,616 | -14% | -$506,664 | |||||
| M | 2019-09-09 | ALDX | Aldeyra Therapeutics, Inc. | Douglas Richard | Dir | P - Purchase | $5.00 | +20,000 | 60,000 | +50% | +$99,963 | |||||
2019-09-10 | XLRN | Acceleron Pharma Inc | Veness Adam M | VP, GC, Sec. | S - Sale | $45.20 | -824 | 16,101 | -5% | -$37,241 | ||||||
2019-09-10 | XLRN | Acceleron Pharma Inc | Kumar Ravindra | SVP, Chief Scientific Officer | S - Sale | $45.24 | -3,389 | 86,986 | -4% | -$153,318 | ||||||
2019-09-10 | XLRN | Acceleron Pharma Inc | Quisel John D | EVP, Chief Business Officer | S - Sale | $45.23 | -3,584 | 59,158 | -6% | -$162,104 | ||||||
2019-09-10 | XLRN | Acceleron Pharma Inc | McLaughlin Kevin F | SVP, CFO, Treasurer | S - Sale | $45.30 | -8,000 | 22,279 | -26% | -$362,400 | ||||||
2019-09-10 | XLRN | Acceleron Pharma Inc | Dable Habib J | CEO, Pres | S - Sale | $45.23 | -5,625 | 70,883 | -7% | -$254,412 | ||||||
| D | 2019-09-09 | SGEN | Seattle Genetics Inc /wa | Siegall Clay B | Pres, CEO | S - Sale+OE | $68.33 | -28,472 | 755,684 | -4% | -$1,945,531 | |||||
2019-09-06 | ORGO | Organogenesis Holdings Inc. | Ades Alan A. | Dir, 10% | P - Purchase | $5.03 | +10,000 | 67,961,823 | 0% | +$50,274 | ||||||
2019-09-09 | AERI | Aerie Pharmaceuticals Inc | Rubino Richard J | CFO | P - Purchase | $19.93 | +5,040 | 339,446 | +2% | +$100,447 | ||||||
2019-09-09 | AERI | Aerie Pharmaceuticals Inc | Anido Vicente Jr | CEO | P - Purchase | $19.01 | +26,250 | 197,631 | +15% | +$498,953 | ||||||
| D | 2019-09-05 | BLUE | Bluebird Bio, Inc. | Gregory Philip D | Chief Scientific Officer | S - Sale+OE | $101.20 | -850 | 29,842 | -3% | -$86,018 | |||||
| M | 2019-09-05 | NK | Nantkwest, Inc. | Thomas John C | Dir | S - Sale | $1.24 | -24,000 | 383,955 | -6% | -$29,790 | |||||
| M | 2019-09-04 | AERI | Aerie Pharmaceuticals Inc | Foresite Capital Management Ii, LLC | 10% | P - Purchase | $18.47 | +115,900 | 2,350,477 | +5% | +$2,140,890 | |||||
| M | 2019-09-03 | ORGO | Organogenesis Holdings Inc. | Ades Alan A. | Dir, 10% | P - Purchase | $4.50 | +105,100 | 67,951,823 | 0% | +$473,209 | |||||
| M | 2019-09-03 | DNLI | Denali Therapeutics Inc. | Watts Ryan J. | Pres, CEO | S - Sale | $18.05 | -8,581 | 2,506,562 | 0% | -$154,894 | |||||
| DM | 2019-09-03 | TWST | Twist Bioscience Corp | Weiss Patrick | SVP, R, D GM Data Storage | S - Sale+OE | $27.66 | -14,728 | 105,287 | -12% | -$407,393 | |||||
2019-09-03 | TWST | Twist Bioscience Corp | Peck Bill | CTO | S - Sale | $28.43 | -20,447 | 702,885 | -3% | -$581,210 | ||||||
| M | 2019-08-21 | TCRR | Tcr2 Therapeutics Inc. | Jovan-Embiricos Morana | 10% | S - Sale | $17.11 | -64,104 | 3,507,157 | -2% | -$1,097,080 | |||||
| D | 2019-09-03 | NBIX | Neurocrine Biosciences Inc | Lippoldt Darin | GC | S - Sale+OE | $100.00 | -6,736 | 20,103 | -25% | -$673,600 | |||||
| D | 2019-09-03 | SGEN | Seattle Genetics Inc /wa | Siegall Clay B | See Remarks | S - Sale+OE | $70.80 | -9,693 | 755,684 | -1% | -$686,257 | |||||
| DM | 2019-08-30 | SGEN | Seattle Genetics Inc /wa | Himes Vaughn B | See Remarks | S - Sale+OE | $72.00 | -13,692 | 187,518 | -7% | -$985,849 | |||||
| D | 2019-09-03 | SGEN | Seattle Genetics Inc /wa | Dansey Roger D | See Remarks | S - Sale+OE | $70.80 | -922 | 106,146 | -1% | -$65,277 | |||||
| D | 2019-09-03 | SGEN | Seattle Genetics Inc /wa | Liu Jean I | See Remarks | S - Sale+OE | $0.00 | -1,779 | 78,120 | -2% | -$0 | |||||
| D | 2019-09-03 | SGEN | Seattle Genetics Inc /wa | Simpson Todd E | See Remarks | S - Sale+OE | $70.80 | -2,092 | 172,567 | -1% | -$148,112 | |||||
| M | 2019-08-30 | AERI | Aerie Pharmaceuticals Inc | Foresite Capital Management Ii, LLC | 10% | P - Purchase | $21.00 | +75,000 | 2,325,477 | +3% | +$1,574,741 | |||||
| D | 2019-09-04 | AMGN | Amgen Inc | Sugar Ronald D | Dir | S - Sale+OE | $206.70 | -2,000 | 14,336 | -12% | -$413,400 | |||||
| D | 2019-08-30 | AMGN | Amgen Inc | Patton Cynthia M | SVP, CCO | S - Sale+OE | $208.07 | -13,426 | 22,361 | -38% | -$2,793,510 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |